The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
CRB-601 and PF-06940434 fall by the wayside.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
Persevera is a bust, but Roche hasn’t given up on the front line.
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
Ono's antisense therapy is to begin its first pivotal trial.
